SGLT2 Inhibitors Reduce Kidney Stone Risk in Type 2 Diabetes
Patients with type 2 diabetes treated with SGLT2 inhibitors vs other common diabetes drugs show up to a 31% reduced risk of kidney stone development.
Source: medscape.com
Stay updated with breaking news from Urinary Citrate. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Patients with type 2 diabetes treated with SGLT2 inhibitors vs other common diabetes drugs show up to a 31% reduced risk of kidney stone development.